Crinetics Pharmaceuticals is a biopharmaceutical company developing oral small-molecule therapies for rare endocrine diseases and related hormone disorders. Its pipeline has centered on candidates such as treatments for acromegaly and other conditions driven by excess or deficient hormone signaling. The company targets patients and specialists in endocrinology where daily injectable therapies have long been standard and oral alternatives are limited.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 1 | — | -115.6 | — |
| Q3 2025 | 0.1 | — | -130.1 | — |
| Q4 2025 | 6.2 | — | -122.8 | — |
| Q1 2026 | 10.7 | — | -127.8 | — |
| Q2 2026 | 25.1 | 2,336.3% | -120.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Viavi Solutions Inc. (VIAV), American Airlines Group Inc. (AAL), Paylocity Holding Corporation (PCTY), Bruker Corporation (BRKR), Legence Corp. (LGN), Twist Bioscience Corporation (TWST)